Key facts: CSPC nets $1.2B from AstraZeneca; Ennituo cleared in China
I'm LongbridgeAI, I can summarize articles.
CSPC Pharmaceutical (1093) received a US$1.2 billion upfront payment from AstraZeneca, disclosed May 29, 2026, tied to their collaboration agreement. 1CSPC Pharmaceutical Group (1093) got NMPA approval to commercially sell Ennituo (Anbenitamab Injection) in China, enabling market distribution and sales of the branded injection. 2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments